POCI PRECISION OPTICS CORPORATION, INC.
Electromedical & Electrotherapeutic Apparatus · Nasdaq · SEC CIK 867840 · Fiscal year ends 06/30
Financial factors as of 2026-09-30 (2027Q1), TTM = sum of the last four quarters
Growth
TTM revenue YoY53.0%
TTM net income YoY59.6%
TTM EPS YoY69.4%
Revenue 3-yr CAGR17.6%
Net income 3-yr CAGR—
Margins
Gross margin19.2%
Operating margin-7.4%
Net margin-7.5%
FCF margin—
EBITDA margin-6.5%
Returns
ROE-15.9%
ROA-9.3%
ROIC (approx.)-16.3%
Asset turnover1.25x
Leverage & solvency
Liabilities / assets34.0%
Debt / equity0.06x
Current ratio2.46x
Interest coverage-17.82x
Cash quality & payout
Operating cash flow / net income0.93x
Accruals ratio-0.6%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2027Q12026-09-30 | 2026Q4*2026-06-30 | 2026Q32026-03-31 | 2026Q22025-12-31 | 2026Q12025-09-30 | 2025Q4*2025-06-30 | 2025Q32025-03-31 | 2025Q22024-12-31 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | $8.15M | $8.77M | $8.71M | $7.37M | $6.68M | $6.18M | $4.19M | $4.53M |
| Cost of revenue | $6.31M | $6.55M | $6.65M | $7.16M | $5.73M | $5.38M | $3.77M | $3.46M |
| Gross profit | $1.84M | $2.22M | $2.06M | $204,660 | $946,358 | $799,186 | $417,975 | $1.07M |
| R&D expense | $306,215 | $204,423 | $267,319 | $249,574 | $311,840 | $228,315 | $211,242 | $317,747 |
| SG&A expense | $2.05M | $2.13M | $1.85M | $1.70M | $2.23M | $1.93M | $2.25M | $1.66M |
| Operating income | -$518,310 | -$106,562 | -$64,462 | -$1.74M | -$1.60M | -$1.36M | -$2.04M | -$910,021 |
| Interest expense | $30,121 | $32,776 | $35,116 | $38,462 | $41,775 | $44,577 | $58,476 | $59,660 |
| Pretax income | — | -$107,534 | -$99,578 | — | — | -$1.40M | -$2.10M | — |
| Income tax | — | -$3,747 | $8,705 | — | — | $1,936 | $0 | — |
| Net income | -$474,854 | -$103,787 | -$108,283 | -$1.78M | -$1.64M | -$1.40M | -$2.10M | -$969,681 |
| EBITDA | -$453,039 | -$42,233 | $11,140 | -$1.67M | -$1.53M | -$1.30M | -$1.98M | -$860,825 |
| EPS (basic) | -0.04 | — | -0.01 | -0.23 | -0.21 | — | -0.30 | -0.15 |
| EPS (diluted) | -0.04 | — | -0.01 | -0.23 | -0.21 | — | -0.30 | -0.15 |
| Weighted avg. shares (diluted) | 10.97M | — | 7.79M | 7.71M | 7.71M | — | 6.92M | 6.35M |
| Balance sheet | ||||||||
| Cash & equivalents | $8.97M | $9.84M | $10.68M | $881,486 | $1.39M | $1.77M | $2.55M | $212,441 |
| Receivables | $5.37M | $5.94M | $6.58M | $4.87M | $4.19M | $4.34M | $3.43M | $3.51M |
| Inventory | $3.52M | $3.83M | $3.70M | $4.26M | $3.88M | $3.56M | $3.67M | $3.85M |
| Current assets | $18.44M | $20.11M | $21.41M | $10.42M | $9.86M | $10.06M | $9.97M | $7.84M |
| PP&E, net | $912,997 | $887,713 | $868,713 | $989,347 | $960,878 | $533,792 | $533,869 | $450,257 |
| Goodwill | $8.82M | $8.82M | $8.82M | $8.82M | $8.82M | $8.82M | $8.82M | $8.82M |
| Intangibles | $206,597 | $212,889 | $215,507 | $219,967 | $226,259 | $232,493 | $236,256 | $292,474 |
| Total assets | $30.62M | $32.34M | $33.69M | $22.90M | $22.38M | $19.79M | $19.62M | $17.51M |
| Current liabilities | $7.50M | $8.83M | $10.19M | $9.95M | $7.62M | $6.15M | $5.01M | $6.41M |
| Short-term debt | $577,898 | $577,898 | $577,898 | $577,898 | $577,898 | $577,898 | $576,405 | $427,763 |
| Long-term debt | $562,023 | $711,305 | $855,780 | $1.00M | $1.14M | $1.29M | $1.44M | $1.61M |
| Total debt | $1.14M | $1.29M | $1.43M | $1.58M | $1.72M | $1.87M | $2.01M | $2.04M |
| Total liabilities | $10.42M | $11.99M | $13.58M | $13.57M | $11.46M | $7.53M | $6.44M | $8.03M |
| Shareholders' equity | $20.20M | $20.35M | $20.11M | $9.33M | $10.92M | $12.26M | $13.18M | $9.48M |
| Net debt | -$7.83M | -$8.55M | -$9.25M | $696,667 | $330,523 | $93,368 | -$536,123 | $1.83M |
| Shares outstanding | 10.99M | 10.97M | 10.93M | 7.72M | 7.71M | 7.71M | 7.67M | 6.36M |
| Cash flow statement | ||||||||
| Operating cash flow | -$672,145 | -$649,109 | -$723,258 | -$256,079 | $78,227 | -$569,235 | -$1.87M | -$786,809 |
| Capital expenditure | $84,263 | — | — | — | $304,731 | $46,224 | $126,815 | $29,821 |
| Free cash flow | -$756,408 | — | — | — | -$226,504 | -$615,459 | -$2.00M | -$816,630 |
| Investing cash flow | -$48,025 | -$80,711 | $49,492 | -$96,342 | -$301,789 | -$83,636 | -$89,752 | -$31,986 |
| Financing cash flow | -$154,083 | -$109,084 | $10.47M | -$158,198 | -$158,068 | -$121,267 | $4.30M | $395,664 |
| Depreciation & amortization | $65,271 | $64,329 | $75,602 | $74,165 | $65,181 | $52,595 | $62,358 | $49,196 |
| Stock-based compensation | $235,528 | $397,193 | $247,528 | $162,081 | $301,639 | $439,874 | $562,964 | $308,206 |
Free plan shows the latest 8 periods; Pro shows all 65 🔒
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.